What is the recommended management for a patient with pulmonary hypertension and relative erythrocytosis (hemoglobin 16.7 g/dL, hematocrit 52 %, red blood cell count 5.89 ×10^6/µL)?

Management of Pulmonary Hypertension with Relative Erythrocytosis

In a patient with pulmonary hypertension and these blood values (Hgb 16.7, Hct 52%, RBC 5.89), you should initiate long-term oxygen therapy (LTOT) if the PaO2 is ≤8 kPa, as the hematocrit of 52% meets the threshold for polycythemia (≥55% is the stricter criterion, but 52% warrants consideration), which is a recognized complication of chronic hypoxemia in pulmonary hypertension. 1

Immediate Assessment Priorities

First, determine the type and severity of pulmonary hypertension through:

• Right heart catheterization to confirm hemodynamics (mean PAP ≥25 mmHg) 2
• Arterial blood gas to measure PaO2
• Echocardiography to assess right ventricular function and estimate pulmonary pressures 3
• Ventilation/perfusion scan to exclude chronic thromboembolic pulmonary hypertension (CTEPH) 3

The elevated hematocrit (52%) suggests secondary erythrocytosis from chronic hypoxemia related to the pulmonary hypertension, rather than primary polycythemia vera, especially if isolated without leukocytosis or thrombocytosis 4, 5.

Oxygen Therapy Decision

British Thoracic Society guidelines specifically address this scenario: LTOT should be ordered for patients with pulmonary hypertension when PaO2 is ≤8 kPa, as oxygen therapy may improve tissue oxygenation and prevent complications associated with hypoxemia, including worsening pulmonary hypertension 1. While the evidence level is Grade D (extrapolated from COPD data), this represents the clearest guideline-based recommendation for your clinical scenario.

The rationale: Chronic hypoxemia drives erythrocytosis as a compensatory mechanism, but this can worsen pulmonary vascular resistance and right heart strain. Correcting hypoxemia addresses the root cause.

Management of the Erythrocytosis

For the elevated hematocrit itself:

• If PaO2 ≤8 kPa: LTOT is the primary intervention 1
• Monitor for symptoms: Look for headache, visual disturbances, pruritus, or signs of hyperviscosity
• Phlebotomy considerations: While there are no clear guidelines for target hematocrit in secondary polycythemia from pulmonary hypertension 5, phlebotomy may be considered if:
  • Hematocrit continues rising despite oxygen therapy
  • Patient develops hyperviscosity symptoms
  • Thrombotic risk appears elevated

Important caveat: Do NOT routinely phlebotomize patients with pulmonary hypertension and secondary erythrocytosis without careful consideration, as the elevated hematocrit may be a necessary compensatory mechanism for oxygen delivery in chronic hypoxemia.

Pulmonary Hypertension-Specific Therapy

The underlying pulmonary hypertension requires classification and targeted treatment:

For Group 1 PAH (if confirmed):

• Refer to pulmonary hypertension center 2
• Consider PAH-specific therapies (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclins) based on functional class 6, 7
• Initial combination therapy with ambrisentan plus tadalafil is superior to monotherapy for treatment-naive patients 7

For Group 3 PH (lung disease-related):

• Optimize treatment of underlying lung disease
• LTOT remains cornerstone 1
• PAH-specific drugs are NOT recommended 3

For Group 4 CTEPH:

• Lifelong anticoagulation mandatory 3
• Surgical pulmonary endarterectomy is treatment of choice if operable 3

Common Pitfalls to Avoid

1. Don't assume polycythemia vera: With isolated erythrocytosis in the setting of pulmonary hypertension, secondary causes are far more likely. JAK2 testing is only indicated if there's concurrent leukocytosis/thrombocytosis or no clear secondary cause 5, 8

2. Don't use PAH-specific drugs empirically: These are contraindicated in Group 2 (left heart disease) and Group 3 (lung disease) pulmonary hypertension and may cause harm 3

3. Don't delay oxygen assessment: Arterial blood gas is essential—pulse oximetry alone is insufficient for LTOT prescription decisions 1

4. Don't overlook CTEPH: This is the only potentially curable form of pulmonary hypertension through surgery, and V/Q scanning is the required screening test 3

Monitoring Strategy

• Repeat complete blood count every 3-6 months
• Serial arterial blood gases if on LTOT
• Functional assessment (6-minute walk distance, WHO functional class)
• Echocardiography to track right ventricular function
• Consider right heart catheterization if clinical deterioration occurs

The key is recognizing that the erythrocytosis is likely a consequence of the pulmonary hypertension-induced hypoxemia, not a separate primary disorder, and treating the underlying hypoxemia with oxygen therapy is the evidence-based approach 1.